T regulatory cell markers in oral squamous cell carcinoma: Relationship with survival and tumor aggressiveness

Oncology Letters

Volumn 1, Issue 1, 2010, Pages 127-132

  Moreira, Geane ^a   Fulgêncio, Lívia Bonfim ^a   de Mendonça, Elismauro Franciscode ^b,c   Leles, Cláudio Rodrigues ^c   Batista, Aline Carvalho ^c   da Silva, Tarcília Aparecida ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Head and Neck Division of Araújo Jorge Hospital   (Brazil)

^c FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

Author keywords

Immune response; Squamous cell carcinoma; T regulatory cells

Indexed keywords

CD4 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIP CARCINOMA; LOG RANK TEST; LYMPHOCYTE COUNT; MALE; MOUTH CARCINOMA; ORAL SQUAMOUS CELL CARCINOMA; REGULATORY T LYMPHOCYTE; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH;

EID: 77955739211     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol_00000023     Document Type: Article

References (41)

1. Hanahan D, Lanzavecchia A and Mihich E: Fourteenth Annual Pezcoller Symposium: the novel dichotomy of immune interactions with tumors. Cancer Res 63: 3005-3008, 2003.
2. Oliveira-Neto HH, Leite AF, Costa NL, et al: Decrease in mast cells in oral squamous cell carcinoma: possible failure in the migration of these cells. Oral Oncol 43: 484-490, 2007.
3. + regulatory T cells. Immunology 109: 319-325, 2003.
4. Wang HY, Lee DA, Peng G, et al: Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 20: 107-118, 2004.
5. Wei WZ, Morris GP and Kong YC: Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol Immunother 53: 73-78, 2004.
6. Wang RF: Regulatory T cells and innate immune regulation in tumor immunity. Springer Semin Immunopathol 28: 17-23, 2006.
7. Yamaguchi T and Sakaguchi S: Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol 16: 115-123, 2006.
8. Chen L: Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 4: 336-347, 2004.
9. + regulatory T cells by TGF-β induction of transcription factor FoxP3. J Exp Med 198: 1875-1886, 2003.
10. Hurwitz AA, Yu TF, Leach DR and Allison JP: CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci USA 95: 10067-10071, 1998.
11. Hurwitz AA, Foster BA, Kwon ED, et al: Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 60: 2444-2448, 2000.
12. Tartour E, Mosseri V, Jouffroy T, et al: Serum soluble interleukin-2 receptor concentrations as an independent prognostic marker in head and neck cancer. Lancet 357: 1263-1264, 2001.
13. Jones E, Dahm-Vicker M, Simon AK, et al: Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun 2: 1-12, 2002.
14. Phan GQ, Yang JC, Sherry RM, et al: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100: 8372-8377, 2003.
15. Curiel TJ, Coukos G, Zou L, et al: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949, 2004.
16. Ghaderi A, Yeganeh F, Kalantari T, et al: Cytotoxic T lymphocyte antigen-4 gene in breast cancer. Breast Cancer Res Treat 86: 1-7, 2004.
17. Wolf D, Wolf AM, Rumpold H, et al: The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 11: 8326-8331, 2005.
18. + regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 12: 5423-5434, 2006.
19. Larkin J, Tangney M, Collins C, et al: Oral immune tolerance mediated by suppressor T cells may be responsible for the poorer prognosis of foregut cancers. Med Hypotheses 66: 541-544, 2006.
20. Downey SG, Klapper JA, Smith FO, et al: Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 13: 6681-6688, 2007.
21. + T cell compartment without affecting regulatory T-cell function. Clin Cancer Res 13: 2158-2167, 2007.
22. Fu J, Xu D, Liu Z, et al: Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 132: 2328-2339, 2007.
23. + regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma. Oncol Rep 18: 1115-1122, 2007.
24. + CD25-high FoxP3+ Treg clones obtained from peripheral blood of patients with cancer. Int J Cancer 121: 2473-2483, 2007.
25. + effector populations in patients with squamous cell carcinoma of the head and neck. Head Neck 29: 120-127, 2007.
26. Loose D, Signore A, Bonanno E, et al: Prognostic value of CD25 expression on lymphocytes and tumor cells in squamous-cell carcinoma of the head and neck. Cancer Biother Radiopharm 23: 25-33, 2008.
27. Bai XF, Liu J, May KF Jr, Guo Y, Zheng P and Liu Y: B7-CTLA4 interaction promotes cognate destruction of tumor cells by cytotoxic T lymphocytes in vivo. Blood 99: 2880-2889, 2002.
28. + T cells. Eur J Immunol 37: 129-138, 2007.
29. Zheng Y and Rudensky AY: Foxp3 in control of the regulatory T cell lineage. Nat Immunol 8: 457-462, 2007.
30. + T-cell subpopulations in head and neck cancers. Clin Cancer Res 12: 465-472, 2006.
31. Böheim K, Denz H, Böheim C, Glassl H and Huber H: An immunohistologic study of the distribution and status of activation of head and neck tumor infiltrating leukocytes. Arch Otorhinolaryngol 244: 127-132, 1987.
32. Antunes JLF, Biazevic MGH, de Araujo ME, Tomita NE, Chinellato LEM and Narvai PC: Trends and spatial distribution of oral cancer mortality in São Paulo, Brazil, 1980-1998. Oral Oncol 37: 345-350, 2001.
33. Vartanian JG, Carvalho AL, Filho MJA, Júnior MH, Magrin J and Kowalski LP: Predictive factors and distribution of lymph node metastasis in lip cancer patients and their implications on the treatment of the neck. Oral Oncol 40: 223-227, 2004.
34. Wong YK, Chang KW, Cheng CY and Liu CJ: Association of CTLA-4 gene polymorphism with oral squamous cell carcinoma. J Oral Pathol Med 35: 51-54, 2006.
35. + Tregs in lymphomas and tumors are complex. Front Biosci 13: 3986-4001, 2008.
36. Schwarz S, Butz M, Morsczeck C, Reichert TE and Driemel O: Increased number of CD25 FoxP3 regulatory T cells in oral squamous cell carcinomas detected by chromogenic immunohistochemical double staining. J Oral Pathol Med 37: 485-489, 2008.
37. + T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res 63: 1555-1559, 2003.
38. Bromwich EJ, McArdle PA, Canna K, et al: The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer. Br J Cancer 89: 1906-1908, 2003.
39. Agarwal A, Rani M, Saha GK, et al: Disregulated expression of the Th2 cytokine gene in patients with intraoral squamous cell carcinoma. Immunol Invest 32: 17-30, 2003.
40. Ebert LM, Tan BS, Browning J, et al: The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Res 68: 3001-3009, 2008.
41. Karanikas V, Speletas M, Zamanakou M, et al: FoxP3 expression in human cancer cells. J Transl Med 6: 19-24, 2008.